Pulse Biosciences PLSE recently announced a strategic shift aimed at accelerating the development and future commercialization of its nPulse Cardiac Catheter Ablation System. The initiative follows ...

Pulse Biosciences (Nasdaq:PLSE) announced a new strategic alignment to focus on its nPulse cardiac catheter ablation system.

Collateral effects on non-target tissue are worse with pulsed-field ablation than with radiofrequency ablation, according to a study published April 24 in JACC: Clinical Electrophysiology. The ...

EDAP TMS SA announced the positive results of its Focal Ablation Versus Radical Prostatectomy (FARP) Study at the AUA Annual Meeting on April 27, 2025. The trial achieved its primary goal, ...

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation ...

Enrollment completed ahead of schedule in the global IDE for Abbott (ABT)'s Volt™ PFA System Global FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor™ ...

A study found that undergoing a cardiac ablation procedure first—before taking any antiarrhythmic therapies—may be the better option for people who have developed a dangerous rhythm after surviving a ...

Share on Pinterest A new study found that ablation is an effective treatment for AFib in most patients. VICTOR TORRES/Stocksy A recent study investigates how well radiofrequency-based ablation treats ...